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Abstract 
Background: Helicobacter pylori (H. pylori) infection is reported to be associated with various extragastrointesti-
nal conditions such as insulin resistance, diabetes mellitus and metabolic syndrome. H. pylori infection and type 2 
diabetes mellitus (T2DM) are associated with oxidative stress, this cross-relation between H. pylori induced infection 
in T2DM and oxidative damage is still debated. Thus, the question arises whether an increase in the serum level of 
8-OHdG and Ox-LDL will occurs in patients with T2DM infected H. pylori; this will be through determination and com-
pare frequency of H. pylori infection in T2DM and non-diabetic patients.
Methods: 100 patients presented with history of epigastric discomfort for more than 1 month; 50 patients with 
T2DM and 50 non-diabetics. Anti-H. pylori IgG using ELISA, fasting and postprandial glucose level, glycated hemo-
globin (HbA1c) and body mass index (BMI) was calculated. Serum 8-OHdG and Ox-LDL was measured using ELISA for 
the 100 patients and 50 control subject.
Results: Rates of H. pylori infection of T2DM and non-diabetic were 66 and 58 %, respectively, (p = 0.001). H. pylori IgG 
antibody was not correlated with HbA1c either in T2DM (p = 0.06) or non-diabetic (p = 0.25). Serum 8-OHdG level 
in T2DM with positive H. pylori infection showed a significant difference compared to non-diabetics with positive H. 
pylori infection (p = 0.001) and higher than that in T2DM with negative H. pylori. A correlation between 8-OHdG con-
centration and HbA1c in T2DM patients infected with H. pylori was observed (r = 0.39, p = 0.02). Serum Ox-LDL level 
in T2DM with positive H. pylori infection showed a significant difference compared to diabetics with both negative H. 
pylori infection and in non-diabetics with positive H. pylori infection (p = 0.001).
Conclusions: Increased levels of oxidative DNA damage (8-OHdG) and Ox-LDL suggest the mechanistic link 
between H. pylori infection combined with diabetes and increased generation of ROS and could play as an important 
image for high risk to atherosclerosis.
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Background
Helicobacter pylori (H. pylori) infection is probably one of 
the most common chronic bacterial infections worldwide 
[1]. The stomach is the primary site of H. pylori infection, 
including chronic active gastritis, peptic ulcer, gastric 
adenocarcinoma and type B low-grade mucosa-associ-
ated lymphoid tissue lymphoma [2]. H. Pylori is respon-
sible for both gastric local inflammation and a systemic 
inflammation leading to extra-gastrointestinal tract 
conditions such as cardiovascular diseases, idiophatic 
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deficiency anemia, diabetes mellitus (DM) and insulin 
resistance [3]. Different studies reported that prevalence 
of chronic H. pylori infection associated with both gas-
trointestinal and extra-intestinal ailments [4–6].
Gastrointestinal inflammation caused by H. pylori can 
influence the absorption of glucose and lipids, which are 
also abnormal in diabetes mellitus [6]. Diabetes has been 
identified as a risk factor for an extragastric manifesta-
tion of H. pylori infection [7, 8]. The relationship between 
H. pylori and DM was first explored in 1989 by Simon 
et al. [9] who found that the prevalence of H. pylori infec-
tion in patients with DM was significantly higher than in 
asymptomatic controls (62 vs 21 %). The link between H. 
pylori infection and diabetes remains controversial, as 
some studies indicated a higher prevalence of infection in 
diabetic patients [10, 11], while others reported no differ-
ence [12, 13].
Recent evidence implicates the pathological involve-
ment of inflammation in type 2 diabetes mellitus 
(T2DM), which is an important process induced by H. 
pylori infection [14]. As insulin resistance can be devel-
oped in the presence of inflammation [15] or as a result 
of alterations in counter regulatory hormones that affect 
insulin [16]. Thus, H. pylori may promote insulin resist-
ance by inducing chronic inflammation and affecting 
insulin-regulating gastrointestinal hormones as reported 
by Aydemir et al. [17].
Furthermore, H. pylori infection is strongly linked to 
the pathogenesis of T2DM, which is associated with a 
general activation of the innate immune system, and a 
chronic, cytokine-mediated state of low-grade inflam-
mation [14]. The host immune response to H. pylori 
infection is complex and involves up regulation of sev-
eral pro-inflammatory cytokines, such as C-reactive 
protein (CRP) [18], interleukin 6 (IL-6), and tumor 
necrosis factor- α (TNF-α) [19], which are implicated in 
insulin resistance and the development of diabetes [20]. 
Thus, a potential relationship between H. pylori infec-
tion and diabetes is highly suspected. For this reason; it 
is expected in our study that, the implication between 
H. pylori and diabetes induces inflammation, accumula-
tion of reactive oxygen species (ROS) and oxidative DNA 
damage in gastric mucosa.
Oxidative stress due to overproduction of ROS through 
either endogenous or exogenous insults can damage cel-
lular macromolecules, leading to DNA damage, protein 
modification, lipid peroxidation and associated with the 
development of several diseases such as cardiovascular, 
chronic inflammation and cancer [21]. ROS production 
has been reported to be increased in DM [22] and H. 
pylori infection [5] which may directly contribute to the 
generation of oxidative stress via several mechanisms.
H. pylori infection induces infiltration and activation of 
neutrophils and macrophages [23]. Enhanced ROS lev-
els due to neutrophil infiltration and increased oxidative 
DNA damage have been reported in H. pylori-infected 
patients [23]. Moreover, neutrophil accumulation and 
oxidative stress at sites of H. pylori-mediated gastric 
inflammation induce enhanced localization of Ox-LDL at 
such gastric inflammatory lesions and increased plasma 
levels of Ox-LDL occur in patients with H. pylori-positive 
chronic gastritis [24].
On the other hand, oxidative stress can be induced in 
hyperglycemia status via glucose autoxidation and the 
formation of advanced glycation end-products (AGE) 
[25]. Other circulating factors that are elevated in diabet-
ics, such as free fatty acids and leptin, also contribute to 
increased ROS generation [26]. Furthermore, oxidative 
stress has been increasingly implicated in the deteriora-
tion of pancreatic islet function [27].
Ox-LDL has been observed to be increased in diabetic 
patients and this may contribute to the increased athero-
genesis in diabetes, regardless of normal lipid levels, 
Ox-LDL levels may be elevated in diabetic patients and 
this may be the explanation for the altered endothelial 
function [28]. Endothelium exposed to Ox-LDL devel-
ops alterations such as endothelial damage. The Ox-LDL 
itself activates inflammatory cells and potentiates the lib-
eration of growth factors from monocytes/macrophage 
[29].
ROS attack guanine bases in DNA easily and form 
8-hydroxydeoxy guanosine (8-OHdG), which can bind 
to thymidine rather than cytosine, based on which, the 
level of 8-OHdG is generally regarded as a biomarker of 
mutagenesis consequent to oxidative stress, and as a risk 
factor for many diseases including H. pylori infection [30] 
and diabetes [31]. A recent study reported an increase in 
the 8-OHdG content in mononuclear cells and ROS level 
in Type I (insulin-dependent) and Type II (non-insu-
lin-dependent) diabetic patients when compared with 
control subjects [32]. Another study reported that H. 
pylori-induced chronic inflammation and oxidative stress 
create an environment conducive to DNA damage and 
tissue injury [33].
The previous reported studies were based on study-
ing the role of oxidative stress in H. pylori and diabetes 
separately. However, to our knowledge, the association 
between diabetes and oxidative status has not been pre-
viously investigated in H. pylori infection. Therefore, 
the goal of this study was to assess the prevalence of H. 
pylori infection in patients with T2DM and to evaluate 
the relationship between the level of oxidative DNA dam-
age 8-OHdG and serum Ox-LDL levels in T2DM patients 
with H. pylori infection.
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Methods
Subjects
This study was conducted in 100 patients with his-
tory of dyspepsia or epigastric discomfort for more 
than 1  month and where known as cases of T2DM for 
approximately 5  years duration. This study was done in 
collaboration between biochemistry department, fac-
ulty of medicine, Umm Al-Qura University, Makkah 
Al-Mukarama, Kingdom of Saudi Arabia and Sadat City 
University, Sadat City, Egypt. Patients with the follow-
ing conditions were excluded from the study: Patients 
of type-I diabetes, pregnancy, prior H. pylori eradication 
therapy, use of antibiotics therapy, history of gastric sur-
gery or cholecystectomy, chronic renal failure requiring 
dialysis treatment and patients who were diagnosed for 
malignancy.
The inclusion criteria of the study was investigated 
for T2DM and H. pylori infection, and divided into two 
groups- A and B, as well as a 50 healthy control group. 
Group-A (labeled diabetic group) contains 50 diabetic 
patients known cases of T2DM with positive or nega-
tive H. pylori infection (40 females, 10 males, mean age 
51.04 ±  7.4  years); while group-B (labeled non diabetic 
group) contains 50 non diabetic patients with positive 
or negative H. pylori infection (19 females, 31 males, 
mean age 43.3  ±  9.3  years). The known cases of DM 
in group-A were also investigated for blood sugar lev-
els (not for diagnostic purpose but to assess the blood 
sugar level that whether it is controlled or uncontrolled). 
Height and body weight were measured using a digital 
scale, and body mass index (BMI) was calculated as fol-
lows: BMI = body weight (kg)/height squared (m2). The 
study protocol was approved by Ethics Review Board for 
Human Studies at Faculty of Medicine, Umm Al-Qurra 
University and conformed to the ethical guidelines of the 
1975 Helsinki declaration.
Samples and laboratory methods
Blood samples were obtained following an overnight 
fasting period according to the diagnostic criteria of DM; 
only patients with fasting blood glucose above 126 mg/
dL or postprandial 2 h after meal above 200 mg/dL. Sam-
ples were withdrawn from a cubital vein into blood tubes 
and immediately serum was separated from the cells by 
centrifugation at 3000  r/min for 10  min and stored in 
refrigerator at 4 °C until processed. Fasting blood sugar 
(FBS) level and postprandial blood sugar (PBS) level 
were measured using an auto analyzer (COBAS  INTE-
GRA 400 PLUS, Roche, Germany). In addition, hemo-
globinA1c (HbA1c) was measured according to DCCT 
(diabetes control and complications trial), as well as 
rapid urease test was determined to check the presence 
of H. pylori.
Quantitative determination of anti‑H. Pylori IgG
H. pylori status was defined by the titer of H. pylori anti-
body using H. pylori IgG enzyme-linked immunosorbent 
assays (ELISA) (Ratio Diagnostics, Frankfurt, Germany) 
for the detection and qualitative determination of IgG 
antibodies to H. pylori in human serum. A value <0.9 is 
considered negative for the presence of detectable IgG 
antibody and values greater than 1.1 indicated the pres-
ence of detectable IgG antibody against H. pylori.
Determination of serum 8‑Hydroxydeoxyguanosine 
(8‑OHdG)
8-OHdG was measured using the commercially available 
Cloud-Clone Crop 8-OHdG Competitive inhibition enzyme 
immunoassay technique kit (Cloud-Clone Crop., USCN 
Life science Inc.; Houston, TX 77,082, USA), intended to be 
used for the in vitro quantitative measurement of 8-OHdG 
in human blood serum. A monoclonal antibody specific to 
8-OHdG has been pre-coated onto a micro plate. A com-
petitive inhibition reaction was then launched between bio-
tin labeled 8-OHdG and unlabeled 8-OHdG (standards or 
samples) with the pre-coated antibody specific to 8-OHdG. 
After incubation the unbound conjugate is washed off. Avi-
din conjugated to horseradish peroxidase (HRP) was then 
added to each micro plate well and incubated for 30  min 
at 37 °C. The amount of bound HRP conjugate was reverse 
proportional to the concentration of 8-OHdG in the sample. 
After addition of the substrate solution and the absorbance 
was measured with a micro-plate reader at a wavelength of 
450 nm, the intensity of color developed was reversed pro-
portional to the concentration of 8-OHdG in the sample. 
The amount of 8-OHdG in the serum was calculated from 
the standard curve and results were expressed as pg/ml.
Determination of oxidized low density lipoproteins 
(Ox‑LDL)
Ox-LDL was measured using the commercially avail-
able Cloud-Clone Crop Ox-LDL Competitive sand-
wich enzyme immunoassay technique kit (Cloud-Clone 
Crop., USCN Life science Inc.; Houston, TX 77082, 
USA), intended to be used for quantitative measure-
ment of Ox-LDL in human blood serum. The micro 
titer plate provided in this kit has been pre-coated with 
an antibody specific to Ox-LDL. Standards and samples 
were then added to the appropriate micro titer plate 
wells with a biotin-conjugated antibody specific to Ox-
LDL. Avidin conjugated to HRP was then added to each 
micro plate well and incubated for 30 min at 37 °C. After 
3,3′,5,5′-Tetramethylbenzidine  (TMB) substrate solution 
is added, only those wells that contain Ox-LDL, biotin-
conjugated antibody and enzyme-conjugated avidin 
exhibited a change in color. The enzyme-substrate reac-
tion terminated by the addition of sulphuric acid solution 
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and the color change was assessed spectrophotometri-
cally at a wavelength of 450  nm. The concentration of 
Ox-LDL in the samples was then determined by compar-
ing the O.D. of the samples to the standard curve.
Statistical analysis
All statistical analyses were done using a Statistical Pack-
age for the Social Sciences (SPSS); v.20 (SPSS Inc., Chi-
cago, IL, USA). Continuous variables were expressed as 
mean ± SD, whereas categorical variables were expressed 
as numbers (percentages). Statistically significant differ-
ences between groups were determined using Student t 
test and Manne Whitney U-test. Statistical comparisons 
between more than three groups such as data relating to 
circadian variation of Ox-LDL and 8-OHdG were per-
formed by 1-way ANOVA. The correlation coefficient 
was obtained by Pearson correlation test. P values less 
than 0.05 were considered to be significant.
Results
Baseline characteristics
Among 100 patients in our study, fifty patients in each 
group, of which 41 (41 %) males and 59 (59 %) females. 
The overall mean age was 47.17 ±  9.2  years. The mean 
age of male’s 46.34 ± 9.52 and 48.37 ± 8.91 years old in 
female patients respectively. The prevalence of H. pylori 
infection among T2DM and non-diabetics patients 
was 66 % (33/50, mean age 51.79 ± 6.9 years) and 58 % 
(29/50, mean age 44.86 ± 10.08 years) respectively. This 
was statistically significant (p = 0.001) (Table 1).
Demographic characteristic are shown in Table 1. Body 
mass index (BMI), the serum glucose level and HbA1c 
were found to be significantly higher in T2DM patients 
than in those non-diabetic patients (p = 0.0001). In addi-
tion, positive H. pylori in T2DM patients was higher in 
HbA1c 6.93  ±  0.69 when compared with positive H. 
pylori in non-diabetic patients 3.97 ±  0.52 (p =  0.001). 
Moreover, BMI was higher in T2DM patients with 
H. pylori infection than in those without, although it 
did not reach statistical significance (28.88  ±  2.68 vs 
27.72 ± 2.22 kg/m2, p = > 0.05).
Qualitative analysis of H. pylori IgG antibody in diabetic 
and non‑diabetic patients
IgG antibodies have been the most specific class of antibod-
ies for the detection of H. pylori infection, and therefore, we 
analyzed IgG antibody for confirmation of H. pylori infec-
tion in 100 patients and 50 control. The mean ± SD of H. 
pylori IgG antibody in T2DM was 63.32 ± 57.66; in non-
diabetics was 39.5 ± 33.90. There was a significant differ-
ence observed between serum H. pylori IgG antibody in 
T2DM patients compared to non-diabetics (p  =  0.003), 
shown in Fig. 1. Furthermore, positive H. pylori infection in 
T2DM patients had the highest concentration of H. pylori 
IgG antibody 94.52  ±  45.9 compared to non-diabetics 
66.01 ±  17.36 and control 0.86 ±  0.52, Significant differ-
ence was observed (p < 0.001) (Table 1).
The correlation between the levels of the H. pylori IgG 
antibody and HbA1c is shown in Fig.  2. H. pylori IgG 
antibody was not correlated with HbA1c either in T2DM 
(Pearson correlation coefficient (r) = −0.26, p = 0.06) or 
in non-diabetic patients (r =  0.16, p =  0.25). Based on 
the simple linear regression of cases with and without 
diabetes (n = 50).
Table 1 Demographic and  biochemical characteristic in  diabetic and  non- diabetic patients with  (+Ve) H. pylori and   
(−Ve) H. pylori infection
* p < 0.05 is considered significant
a  References values: fasting blood glucose (F.B.S) 80–120 mg/dl; 2-hours postprandial blood glucose (2 h.pp.B.S)110–140 mg/dl; hemoglobin A1c (HbA1c) 3–6.5 %
b  The prevalence of H. pylori infection among diabetic and non-diabetics patients was 66 and 58 % (P = 0.001). Positive (+Ve) H. pylori infection and negative (−Ve) H. 
pylori infection
Mean ± SD
Healthy (n = 50) Non‑diabetic (n = 50) Diabetic (n = 50) P value*
−ve H. pylori −ve H. Pylori  
(n = 21)
+ve H. Pylori  
(n = 29)b
−ve H. Pylori  
(n = 17)
+ve H. Pylori  
(n = 33)b
M/F 41/9 7/10 3/30 12/9 19/10 <0.05*
Age (years) 27.18 ± 4.39 41.14 ± 7.95 44.86 ± 10.08 49.59 ± 8.47 51.79 ± 6.95 <0.0001*
BMI (Kg/m2) 25.52 ± 1.11 25.86 ± 1.68 27.72 ± 2.22 28.53 ± 2.24 28.88 ± 2.68 >0.05
F.B.S (mg/dl)a 78.64 ± 5.15 81.81 ± 7.08 82.79 ± 8.00 187.41 ± 57.32 182.91 ± 57.55 <0.0001*
2 h.PP.B.S (mg/dl)a 93.14 ± 6.99 101.67 ± 7.96 101.10 ± 12.39 341.76 ± 67.14 321.06 ± 79.81 <0.0001*
HbA1C %a 3.39 ± 0.49 3.84 ± 0.70 3.97 ± 0.52 7.30 ± 0.55 6.93 ± 0.69 <0.001*
H. Pylori IgG 0.86 ± 0.52 3.23 ± 1.73 66.01 ± 17.36 2.46 ± 2.20 94.52 ± 45.9 <0.001*
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Distribution of serum 8‑OHdG as an oxidative DNA 
damage
8-OHdG was measured as an indicator of oxidative 
damage of DNA. 8-OHdG content in control sub-
jects ranged between 43.29 and 108.08  pg/ml, mean 
84.87 ± 16.17 pg/ml. In T2DM patients, 8-OHdG con-
tent of oxidative damage of DNA was greater than con-
trols, 178.35  ±  26.23  pg/ml (range134.55–230.28  pg/
ml, p  =  0.001). In non-diabetic patients, 8-OHdG 
content was also significantly higher than in con-
trols 126.78  ±  27.91  pg/ml for oxidative DNA dam-
age (p  =  0.001). In addition, there was a significant 
difference observed between serum 8-OHdG level in 
T2DM patients compared to non-diabetics (p = 0.001) 
(Fig. 3).
Serum 8‑OHdG levels in T2DM and non‑diabetic 
with positive H. pylori infection
Serum 8-OHdG level in T2DM patients with positive 
H. pylori infection was 188.13 ±  25.40  pg/ml, a signifi-
cant difference compared to non-diabetics with posi-
tive H. pylori infection 148.07 ± 19.55 pg/ml (p = 0.001) 
(Table 2). Furthermore, in T2DM group, serum 8-OHdG 
level was higher with positive H. pylori infection 
188.13 ± 25.40 pg/ml than in negative H.pylori infection 
159.38 ± 15.40 pg/ml (p = 0.001) shown in Table 2.
Correlation between OxLDL and HbA1c in T2DM 
and non‑diabetic infected with H. pylori
We observed a correlation between 8-OHdG concen-
tration and HbA1c in T2DM patients infected with H. 
pylori (r = 0.39, p = 0.02). On the other hand, no correla-
tion was observed between 8-OHdG concentration and 
HbA1c in non-diabetic patients infected with H. pylori 
(r = 0.12, p = 0.6); this correlation is shown in Fig. 4.
Distribution of serum Ox‑LDL
Normal circulating levels of OxLDL level as deter-
mined in normal volunteers subjects ranged between 
3.81 and 69.12 U/dL, mean 24.70 ± 12.36 U/dL. Serum 
Ox-LDL levels in patients with T2DM 106.21 ± 35.1 U/
dL were significantly higher than in control subjects 
(p = 0.001). In non-diabetic patients, serum OxLDL level 
(57.76  ±  32.1  U/dL) was also significantly higher than 
in controls for oxidation of LDL (p  =  0.001). In addi-
tion, there was a significant difference observed between 
Serum Ox-LDL levels in T2DM patients compared to 
non-diabetics (p = 0.001) (Fig. 5).
Serum Ox‑LDL levels in T2DM and non‑diabetic 
with positive H. pylori infection
Serum OxLDL level in T2DM with positive H. pylori 
infection was 116.79  ±  30.29  U/dL, a significant 
Fig. 1 Box plot for H. pylori IgG concentration in non-diabetic and diabetic patients. The box represents the interquartile range. The whiskers indicate 
the highest and lowest values, and the line across the box indicates the median value. Overall significance of differences between non-diabetic and 
diabetic group was determined by 1-way ANOVA
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difference compared to diabetics with negative H. 
pylori infection 85.68 ±  35.69 U/dL or in non-diabetics 
with positive H. pylori infection 72.31  ±  33.80  U/dL 
(p = 0.001) (Table 2).
Correlation between OxLDL and HbA1c in T2DM 
and non‑diabetic infected with H. pylori
There was no correlation between OxLDL concentra-
tion and HbA1c either in T2DM patients infected with 
H. pylori (r = 0.07, p = 0.69) or in non-diabetic patients 
infected with H. pylori (r = 0.02, p = 0.9), this correlation 
was shown in Fig. 4.
Discussion
The link between H. pylori infection and diabetes remains 
controversial. Some studies indicated a higher prevalence 
of infection in diabetic patients [10, 11], and other studies 
reported no difference [12, 13]. Previous reports, based 
on serologic antibody detection, have found a high preva-
lence of H. pylori infection among diabetics as compared 
to the general population [34–36]. The prevalence of H. 
pylori infection ranged between 30 and 80  % in previ-
ously reported studies [34, 37].
There are several lines of evidence to implicate 
increased susceptibility to infection in diabetic patients, 
Fig. 2 Correlation between HbA1c in non-diabetic and diabetic patients measured by ELISA (expressed in %) and concentration of H. pylori IgG 
(expressed in U). The levels of H. pylori IgG (y axis) were correlated with those of  % HbA1c (x axis). No association was observed in two groups. Based 
on the simple linear regression of cases with HbA1c (n = 50 for each group)
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where the mechanisms underlying the pathogenesis 
of diabetes are complex, involving insulin resistance, 
chronic inflammation, insulin secretion deficiency as a 
result of pancreas β-cell dysfunction, glucotoxicity, and 
lipotoxicity [14].
In our study, there was a significant difference in the 
prevalence of H. pylori between cases and controls 
(p  =  0.001), using serological method for diagnosis of 
H. pylori infection. The results therefore showed that H. 
pylori infection is significantly associated with T2DM in 
our study population. Moreover, there was a significant 
association between the infection incidence of H. pylori 
among T2DM patients compared to non-diabetic; 66  % 
(33/50) and 58  % (29/50) respectively (p  =  0.001). No 
correlation was seen between the level of the H. pylori 
IgG antibody and HbA1c % in both groups, T2DM and 
non-diabetic. Accordingly, no association instigated 
between prolonged high levels of glucose and the pres-
ence of H. pylori infection. The relationship between the 
levels of the H. pylori IgG antibody and HbA1c was not 
clear due to methodological pitfalls in other studies [3]. 
These pitfalls were selection of inappropriate or insuf-
ficient methods used for detecting of H. pylori infec-
tion and due to population differences, among different 
studies.
The prevalence of H. pylori infection in diabetic 
patients was different in previous reports. Controver-
sial results of prevalence rates may be related to the 
Fig. 3 Box plot for 8-OHdG as an indicator of oxidative damage of DNA in non-diabetic, diabetic patients and control. The box represents the inter-
quartile range. The whiskers indicate the highest and lowest values, and the line across the box indicates the median value. Overall significance of 
differences between non-diabetic and diabetic group was determined by 1-way ANOVA
Table 2 Distributions of 8-OHdG and Ox-LDL levels in diabetic and non- diabetic patients with (+Ve) H. pylori or (−Ve) H. 
pylori infection
* p < 0.05 is considered significant
Mean ± SD
Healthy (n = 50) Non‑diabetic (n = 50) Diabetic (n = 50) P value
−ve H. pylori −ve H. Pylori  
(n = 21)
+ve H. Pylori  
(n = 29)
−ve H. Pylori  
(n = 17)
+ve H. Pylori  
(n = 33)
8-OHdG (pg/ml) 84.87 ± 16.17 98.65 ± 9.47 148.07 ± 19.55 159.38 ± 15.40 188.13 ± 25.40 0.001*
Ox-LDL (U/dL) 24.70 ± 12.36 37.68 ± 15.53 72.31 ± 33.80 85.68 ± 35.69 116.79 ± 30.29 0.001*
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Fig. 4 Correlation between HbA1c in non-diabetic and diabetic patients with positive H. pylori (expressed in  %) and a DNA damage 8-OHdG 
(expressed in pg/ml). b Oxidized LDL (expressed in U/dL). The levels of 8-OHdG or Ox-LDL (y axis) were correlated with those of HbA1c (x axis). An 
association was observed between HbA1c in diabetic patients with positive H. pylori and 8-OHdG (r = 0.39, p = 0.02). No association was observed 
between HbA1c in non-diabetic and diabetic patients with positive H. pylori and Ox-LDL. Based on the simple linear regression of cases with posi-
tive H. pylori in non-diabetic and diabetic patients
Fig. 5 Box plot for oxidized LDL in non-diabetic, diabetic patients and control. The box represents the interquartile e range. The whiskers indicate 
the highest and lowest values, and the line across the box indicates the median value. Overall significance of differences between non-diabetic and 
diabetic group was determined by by 1-way ANOVA
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epidemiological distribution of infection, nonhomoge-
neous patient groups or the kind of diagnostic method 
to detect infection. A seroprevalence study performed 
in Netherland reported that the frequency of H. pylori 
infection was higher in diabetic patients in comparison 
with the control subjects [38]. Another seroprevalence 
study in United Arab Emirates showed that positive anti-
body titer for H. pylori infection (IgG > 300) in diabetics 
was 76.7 % compared to non-diabetics 64.8 % [38].
In contrast, other studies that showed no association 
between T2DM and H. pylori infection. In a seropreva-
lence study frequency of H. pylori infection was 33 and 
32 %, in patients with diabetes and controls respectively 
[39]. Demir et al. showed that the prevalence of H. pylori 
infection was 61.7 and 58.5  %, among T2DM and non-
diabetics respectively [40].
Several hypotheses were presented to confirm the 
higher prevalence of H. pylori infection in diabetic 
patients such as insulin resistance and abnormal insu-
lin secretion were central to the development of T2DM. 
One of these hypothesis confirm that; H. pylori infec-
tion brings about chronic low grade inflammation with 
up regulation of several cytokines such as CRP, TNF and 
interleukin (IL)-1β, which may influence insulin action 
and pancreatic β cell secretion. The other one; H. pylori-
induced gastritis can potentially affect the secretion of 
gastric hormones, including leptin, ghrelin, gastrin, and 
somatostatin, which could affect insulin sensitivity and 
glucose homeostasis. In addition, other mechanisms and 
mediators may be involved in the possible causative rela-
tionship between H. pylori infection and T2DM [14].
Oxidative stress associated with the production of ROS 
has been shown to play an important role in the patho-
genesis of diabetes [41] and H. pylori infection [42]. 
Excess ROS would accelerate oxidative damage to DNA 
and to other macromolecules, such as proteins and lipids. 
The present study is one of the few studies which investi-
gated the relationship between Ox-LDL and 8-OHdG, a 
marker of systemic oxidative stress with H. pylori-posi-
tive in T2DM patients.
Our data demonstrated that T2DM patients with posi-
tive H. pylori infection had much higher levels of serum 
Ox-LDL (116.79  ±  30.29  U/dL) compared with their 
respective controls. We found no previous reported data 
linking between OxLDL and T2DM combined with H. 
pylori infection. However, Koichi Ono [43] showed Ox-
LDL levels were significantly higher in diabetic patients 
(n  =  30) than in control patients. While, Kayo et  al. 
reported no difference in Ox-LDL levels among patients 
with H. pylori infection and control subjects [24].
Several studies demonstrated that Ox-LDL is a key 
factor in the initiation and progression of atherosclero-
sis [44]. Recently, positive associations between chronic 
H.pylori infection and coronary heart disease has been 
reported [45]; other studies demonstrated that DM con-
sidered a risk factor for atherosclerosis and asymptomatic 
low grade inflammation occurs prior to unconcealed vas-
cular lesions [28]. According to these hypotheses, athero-
sclerosis is considered a process involving the interplay of 
inflammation and oxidative stress.
Our data also indicated that there was a significant dif-
ference observed between serum Ox-LDL levels in T2DM 
patients with positive H. pylori infection compared to 
non-diabetics with positive H. pylori infection. Our result 
is supported by the report of Toshima et  al. which indi-
cated a significant increase in plasma Ox-LDL in diabet-
ics [46]. In addition, Koichi Ono has shown increased 
susceptibility of LDL to oxidation in diabetics [43]. 
Although, there were other reports indicating no increase 
in Ox-LDL in diabetics [47, 48]. A potential explanation 
for these discrepant results lies in the hypothesis that 
patients with DM are more predisposed to infections and 
severe diseases because of cellular immunity disorders 
and phagocyte dysfunction caused by hyperglycemia and 
decreased vascularization. Therefore, patients with DM 
accompanied with H. pylori infection support the concept 
that oxidative stress associated with neutrophil accumula-
tion and activation plays a role in the inflammatory pro-
cess [24]. Myeloperoxidase (MPO), a strong pro-oxidant 
enzyme released from activated neutrophils, has been 
found to be capable of oxidizing LDL [49]. These hypoth-
eses suggest the possibility that MPO secreted from acti-
vated neutrophils in H. pylori-mediated gastritis lesions 
may induce LDL oxidation.
There was no correlation between serum Ox-LDL lev-
els and HbA1c in T2DM (r = 0.07, p = 0.69) and non-dia-
betic (r = 0.02, p = 0.9) patients with positive H. pylori. 
Koichi Ono and Toshima et al. also found no correlation 
between plasma Ox-LDL and HbA1c levels in diabetic 
patients than in non-diabetic patient [43, 46]. Moreover, 
our data showed no correlation between serum Ox-LDL 
levels and positive H. pylori and negative H. pylori infec-
tion in diabetic group.
Significantly raised levels of a specific marker of oxida-
tive damage to DNA; 8-OHdG, were reported in H. pylori 
infection [21] and diabetics [32, 50]. As DNA damage is 
efficiently repaired by cellular enzymes, its measurement 
gives a snapshot view of the level of oxidative stress, in con-
trast to measurement of oxidation of other biomolecules 
which are not repaired and/or have a slow turnover, such 
as lipids or proteins. DNA oxidation may therefore be of 
considerable value in following the progress of the disease 
and its metabolic control [51]. A positive association has 
been demonstrated between H. pylori infection and diabe-
tes with increased oxidative stress. Therefore, our obser-
vations showed that diabetic patients combined with H. 
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pylori infection have significantly increased oxidative DNA 
damage. We found a significant increase in serum 8-OHdG 
level in T2DM (188.13 ±  25.40  pg/mL) and non-diabetic 
(148.07  ±  19.55  pg/mL) patients with positive H. pylori 
compared to their respective controls (84.87 ±  16.17  pg/
mL), confirming the report of Dandong et al. [31].
Moreover, there is greater oxidative DNA damage in 
T2DM patients with positive H. pylori than non-diabet-
ics with positive H. pylori infection. Yongsheng Ma et al. 
[21] showed a significant increase of 8-OHdG in H. pylori 
positive and negative gastric cancer patients. An associa-
tion between poor glycaemic control in T2DM patients 
and oxidative stress has been established [40, 52]. This 
study indicates a correlation between 8-OHdG concen-
tration and HbA1c in T2DM patients infected with H. 
pylori (r = 0.39, p = 0.02). Furthermore, our data showed 
that hyperglycemia implicated with H. pylori infection 
might lead to increased 8-OHdG level in serum through 
the overproduction of ROS. This explain why 8-OHdG 
has been used widely in many studies as endogenous oxi-
dative DNA damage. 8-OHdG can serves as a useful bio-
marker for the evaluation of oxidative stress in diabetic 
patients with H. pylori infection.
Conclusion
In summary, the present study suggests that infection H. 
pylori in T2DM was higher compared to non-diabetic 
population and appears not to be associated with glyce-
mic control; T2DM seems to be associated with increased 
oxidative stress in H. pylori infection. This is the first 
report as known of a direct association between oxida-
tive DNA damage, serum Ox-LDL levels and T2DM 
patients companied with positive H. pylori infection. Fur-
thermore, 8-OHdG is one of the predominant agents of 
free-radical-induced oxidative lesions. In our study, we 
observed that significantly elevated serum Ox-LDL levels 
in T2DM patients with positive H. pylori infection, sug-
gesting hypothesis that high serum level of Ox-LDL levels 
in T2DM patients with positive H. pylori infection con-
sidered as a risk factor to atherosclerotic vascular disease 
and further studies are needed to confirm this hypothesis.
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